tbuckley/cabot-search huggingface dataset:
Impact of radiotherapy on quality of life in elder women with localized breast cancer. A prospective study
Authors: J. I. Arraras, F. Arias, A. Manterola, M. A. Dominguez, E. Villafranca, E. Martinez, J. J. Illarramendi, E. Salgado, R. Vera
Journal: Journal of Clinical Oncology (2007)

19656 Background: the aims of the present study was to evaluate the impact of the radiotherapy in the Quality of Life (QL) in a sample of breast cancer elder patients with localized stages. Methods: The sample size was previously calculated using the program GRANMO 5.2 (Power O.8, a=0.01). During 2005, forty eight patients aged 65 years and older, stages I to III who started radiotherapy with or without hormonetherapy, have filled in the EORTC QLQ-C30 and QLQ-BR23 Quality of Life questionnaires three times: prior, end, and six weeks after the radiotherapy. Demographic data, performance status (Karnfosky scale), Daily Living Activities (DLA) with the IDDD scale, toxicity (CTC v2.0), co-morbidity and other clinical data have also been recorded Statistical analysis: Quality of Life and DLA scores, changes in them among the three assessments (Friedman, with Wilcoxon and Bonferroni criteria) have been calculated. Results: Quality of Life and DLA scores have been high in most dimensions in the three measurements. Moderate limitations (&gt;30 points) have appeared in global Quality of Life, future worries, sexuality scales in the three measurements, and insomnia in the second. There are no significant differences in QL scores between the first and third measurements. In the second measurement there are moderate worsening (between 10 and 20 points) in fatigue, pain and breast symptoms and little (&lt;10) in role, that have recovered in the third measurement. There has also been improvements between the second and third measurement in arm symptoms and global QL. No changes in DLA among the three measurements. Conclusions: Quality of Life in the elder patients has been good and the treatment adequately tolerated. Limited changes have appeared in treatment related areas that have recovered after a short follow-up period. Age should not be the only factor to consider when deciding the treatment protocol to administer. It would be desirable to confirm our results with a bigger sample. No significant financial relationships to disclose.
Combining lapatinib (GW572016) with anti-erbB2 antibodies elicits synergistic apoptotic effects in erbB2 overexpressing breast cancer cells
Authors: N. Spector, L.-H. Liu, C. Gerard, P. N. Baudson, T. Ory, P. Ho, W. Xia
Journal: Journal of Clinical Oncology (2005)

557 Background: Combining non-cross resistant agents is the mainstay of cancer treatment. The question is whether evaluate combining a small molecule ErbB1/ErbB2 kinase inhibitor with anti-ErbB2 antibodies will elicit additive or synergistic anti-tumor effects. Methods: ErbB2 overexpressing breast cancer cell lines (BT474, SKBR3) were treated with (i) sub-lethal concentration of lapatinib (100nM), (ii) trastuzumab (10μg/kg), (iii) Pab (100μg/ml)- antisera from rabbits vaccinated with an human ErbB2 fusion protein, or (iv) lapatinib combined with (ii) or (iii). Apoptosis was determined after treatment. Immunoblot analysis was performed on mediators of tumor cell growth and/or survival (e.g., p-ErbB2, p-ErbB3, p-Erk1/2, p-Akt, survivin). Results: Annexin V staining (apoptosis) remained essentially unchanged in the cells following treatment with lapatinib, Pab, or trastuzumab alone. Combination lapatinib with either Pab or trastuzumab resulted in a synergistic pro-apoptotic effect and complete inhibition of survivin protein with consequential increased apoptosis. Conclusions: Combining lapatinib with anti-ErbB2 antibodies resulted in synergistic tumor cell killing in ErbB2 overexpressing breast cancer cell lines. Inhibition of survivin protein through this combination strategy correlates best with induction of tumor cell death. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration GlaxoSmithKline, GlaxoSmithKline Biologics GlaxoSmithKline
Osteonecrosis of the Jaw in Multiple Myeloma Patients (the IFM Registry).
Authors: Jean Gabriel Fuzibet, Marie Hélène Viellard, Benoit B.R. Rossignol, Chantal C.D. Doyen, Cyril Hulin, Laurent L.G. Garderet, Michel M.B. Blanc, Gerald Marit, Thierry T.F. Facon, Philippe Moreau
Journal: Blood (2007)
Targeted therapy at the end of life and the impact on health care utilization.
Authors: Heidi Yeung, Parsa Salehi, James Don Murphy
Journal: Journal of Clinical Oncology (2014)

116 Background: The use of targeted therapy has steadily increased over the past decade, though the impact of targeted agents on patterns of care at the end-of-life life remains unknown. The purpose of this study was to explore the influence of targeted therapy on end-of-life care in a large population-based database. Methods: We identified 14,398 patients from the SEER-Medicare linked database with metastatic breast, lung, or colorectal cancer diagnosed between 2000 and 2009 who received conventional cytotoxic chemotherapy or targeted therapy in the last 3 months of life. Multivariate logistic and linear regression models were used to determine the impact of targeted therapy on the following endpoints in the last 3 months of life: emergency department (ED) visits, hospitalizations, and hospice utilization. Analyses were adjusted for differences in patient age, gender, race, comorbidity, socioeconomic status, and geography. Results: Among the whole study cohort 83% of patients received chemotherapy alone, 12% received chemotherapy with targeted therapy, and 5% received targeted therapy alone. The delivery of any targeted therapy in the last 3 months increased across the study period, from 1.5% in 2000 to 28% in 2009. Compared to patients treated with chemotherapy alone, those treated with targeted therapy alone had lower rates of ED visits (adjusted odds ratio [aOR]=0.81, p=0.01), lower rates of hospitalization (adjusted odds ratio [aOR]=0.69, p&lt;0.0001), no difference in overall hospice utilization rates, though had longer stays on hospice (5.1 days longer, p&lt;0.0001). Compared to patients treated with chemotherapy alone, those treated with both chemotherapy and targeted therapy had no difference in ED visits or hospitalization admission rates, though had decreased rates of hospice utilization (aOR = 0.79, p&lt;0.0001), and shorter stays on hospice (2.7 days longer, p&lt;0.0001). Conclusions: This study found that targeted therapy was associated with varying patterns of healthcare utilization at the end-of-life, though these differences could be influenced by unknown confounding variables. Future research should focus on defining the specific impact of targeted therapy on quality of life at the end-of-life.
Assessment of the safety and efficacy of percutaneous cryoablation for lung tumors
Authors: Y. Yamauchi, Y. Izumi, N. Tsukada, K. Asakura, M. Inoue, H. Yashiro, S. Nakatsuka, M. Kawamura
Journal: Journal of Clinical Oncology (2009)

7592 Background: Percutaneous cryoablation using high resolution fluoroscopic CT guidance under local anesthesia offers a potential tool for local control of lung tumors in combination with systemic treatments. In this study, we retrospectively analyzed the safety, and efficacy of percutaneous cryoablation for lung tumors (PCLT). Methods: This study was approved by the institutional review board. From October 2002, PCLT was performed in patients who either did not oncologically fulfill the indications for resection, or refused resection. CT scan was examined every 3 months after PCLT. &gt;20% increase in the treated lesion size was diagnosed as local failure. Survival analysis was done by Kaplan-Meier. Results: There were 147 patients (95 male, 52 female, mean age 60, 20 primary lung cancer, metastases; 29 of lung cancer, 35 of colorectal cancer, 63 of other sites). 251 sessions were done for 462 tumors. Mean tumor diameter was 18.3mm. PCLT was well tolerated in most patients. In 1 case, broncho-thoracic fistula occurred in the treated region which lead to empyema. Other complications were pneumothorax (153 sessions, 61%, chest tube required in 23 sessions), pleural effusion (160 sessions, 64%), and transient hemoptysis (82 sessions, 33%). Overall one- and two-year local control rates were 81.0% and 59.1%, respectively. Overall one- and two-year survival rates were 80.0% and 54.5%, respectively. In the 1–20 mm sized (n=362) vs. over 21mm sized (n=100) lesions, the local control rates at one year were 84% vs. 56% (p=0.0007), and at two years were 63% vs. 35% (p=0.017), respectively. There were no differences in local control between primary and metastatic tumors, carcinomas and sarcomas. Survival of patients whose lesions were limited to 1–20mm (n=89) was prolonged vs. those who had at least one over 21mm lesion (n=58) (p=0.01). However, one, and two-year survival rates did not differ significantly between these groups (one-year; 85.5% vs. 71.7% (p=0.07), two-year; 60.7% vs. 46.5% (p=0.16)). Conclusions: PCLT was minimally invasive and safe. 1–20mm tumors were good candidates. Contribution of PCLT to survival was not clear in this mixed patient population. To improve local control in over 20 mm tumors, we are computer simulating freezing kinetics to optimize the number and the positioning of the probes. No significant financial relationships to disclose.
Different effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple-negative invasive ductal breast carcinoma
Authors: J. Wesseling, H. Hartog, H. Horlings, B. van der Vegt, A. Ajouaou, B. Kreike, M. van de Vijver, G. H. de Bock, M. Boezen, W. T. van der Graaf
Journal: Journal of Clinical Oncology (2009)

3546 Background: The insulin-like growth factor type 1 receptor (IGF-1R) is involved in progression and sensitivity to systemic treatment of breast cancer. Moreover, targeted inhibition of IGF-1R is likely to be beneficial in systemic treatment. However, it is unknown how to select patients for IGF-1R targeted therapy. Therefore, we studied the relation between IGF-1R expression and prognosis in invasive ductal breast carcinomas. Methods: Immunohistochemistry was performed on tumor tissue of a consecutive cohort of 429 female patients treated for operable primary invasive ductal breast carcinoma. TMA sections were stained with antibodies against IGF1-R, insulin receptor (IR), ER, PR, HER-2, epidermal growth factor receptor (EGFR) and phosphorylated-Akt (p-Akt). Cytoplasmic and membranous IGF-1R staining were scored separately, as the relevance of IGF-1R cellular localization is yet unknown. Associations between IGF-1R expression with clinical and tumor characteristics were evaluated in a multivariate Cox regression model. To study in more detail the prognostic role of IGF-1R expression in triple negative invasive ductal carcinomas (TN IDCs), 51 TN IDCs from the series described above were combined with 64 TN IDCs from an independent dataset with similar patient and clinico-pathological characteristics. Results: Patients with tumors expressing both ER and cytoplasmic IGF-1R have a longer disease free survival (HR = 0.20; 95% CI 0.07 - 0.63; p-value = 0.006) and breast cancer specific survival (HR = 0.20, 95% CI 0.07 - 0.63, p-value = 0.002), independent of other known prognostic factors. Conversely, in the combined series of 105 TN IDCs, cytoplasmic IGF-1R expression was associated with a shorter disease free survival (HR = 2.29; 95% CI 1.08 - 4.48, p-value = 0.03). In a multivariate model including known prognostic factors, cytoplasmic IGF-1R expression was nearly significantly related to a shorter disease free survival (HR 2.06; 95% CI 0.95 - 4.47; p = 0.07). Conclusions: The favorable versus unfavorable association with prognosis of IGF-1R expression in ER positive versus TN IDCs may provide new opportunities to select patients for IGF-1R targeted therapy. No significant financial relationships to disclose.
A phase II trial of celecoxib, irinotecan, and capecitabine in metastatic colorectal cancer
Authors: B. F. El-Rayes, M. M. Zalupski, A. F. Shields, L. K. Heilbrun, T. Bekaii-Saab, U. Vaishampayan, P. A. Philip
Journal: Journal of Clinical Oncology (2005)

3677 Background: The cyclooxygenase-2 (COX-2) enzyme is overexpressed in the majority of colorectal cancers. Inhibition of the COX-2 enzyme can sensitize colorectal cancer cells to the apoptotic effects of chemotherapeutic agents and block angiogenesis. This phase II study was undertaken to determine the effects of adding celecoxib to the capecitabine and irinotecan regimen. Methods: The primary objective was to estimate the objective response rate of patients with metastatic colorectal cancer treated with irinotecan, capecitabine, and celecoxib. Previously untreated patients, except for adjuvant therapy, with metastatic colorectal adenocarcinoma were eligible for this study. Patients received irinotecan 70 mg/m2 (over 30 minutes) on days 1 and 8, and capecitabine 2,000 mg/m2/day from day 1 to 14 of a 21-day cycle. Celecoxib was administered at a dose of 400 mg twice-daily starting on day -7 until termination from study. Results: A total of 38 patients (median age 56 years) have been enrolled on the study. Median performance status was 1. A total of 177 cycles (range 0–12) were administered. In an intention to treat analysis, objective response and stable disease were seen in 41% (90% CI; 0.26–0.57) and 31%, respectively. The median response duration was 6.5 months. No disease progression has been observed in 26 patients. The median progression free survival was 7.1 months (90%CI; 5.7–11.3). No grade 4 toxicities or treatment related deaths were observed. The only grade 3 toxicities were diarrhea (32%), hand-foot syndrome (6%), nausea (16%), vomiting (13%) and neutropenia (9%). Conclusion: Celecoxib can be safely administered in combination with irinotecan and capecitabine. Lowering the dose intensity of irinotecan in this study did not appear to compromise the treatment outcome and improved the therapeutic index of this combination. Based on the observed progression free survival and response rate, the regimen has promising activity. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech Aventis, Lilly Oncology, Roche
Histochemistry of Gamma-Glutamyl Transpeptidase in Rat Liver During Aflatoxin B1-Induced Carcinogenesis2
Authors: Mbowa M. R. Kalengayi, Guido Ronchi, Valeer J. Desmet
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Histochemistry of Gamma-Glutamyl Transpeptidase in Rat Liver During Aflatoxin B1-Induced Carcinogenesis Get access Mbowa M. R. Kalengayi, Mbowa M. R. Kalengayi Search for other works by this author on: Oxford Academic PubMed Google Scholar Guido Ronchi, Guido Ronchi Search for other works by this author on: Oxford Academic PubMed Google Scholar Valeer J. Desmet Valeer J. Desmet Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 55, Issue 3, September 1975, Pages 579–588, https://doi.org/10.1093/jnci/55.3.579 Published: 01 September 1975 Article history Received: 04 October 1974 Revision received: 15 April 1975 Accepted: 21 May 1975 Published: 01 September 1975
A novel leukocyte differentiation antigen: two monoclonal antibodies TM2 and TM3 define a 120-kd molecule present on neutrophils, monocytes, platelets, and activated lymphoblasts
Authors: H Ohto, H Maeda, Y Shibata, RF Chen, Y Ozaki, M Higashihara, A Takeuchi, H Tohyama
Journal: Blood (1985)
Experiences of the first community hospital to submit specimens for the Cancer Genome Atlas (TCGA) project.
Authors: B. M. Rabeno, M. V. Iacocca, J. Painter, C. Czerwinski, S. Carter
Journal: Journal of Clinical Oncology (2010)

e12035 Background: In September 2008, the Helen F. Graham Cancer Center and Christiana Care Health System received an award from the National Cancer Institute (NCI) to collect glioblastoma multiforme (GBM), squamous cell carcinoma of the lung, and ovarian serous cystadenocarcinoma tumor tissue along with corresponding normal specimens for TCGA. By January 2009 all of the required documentation including standard operating procedures, consent, and material transfer agreement had been submitted and IRB approval was obtained. In February 2009 tissue collection commenced. Methods: Implementation required addition of personnel, as well as buy-in from participating departments and individuals, and a continuing education plan. The addition of five full-time positions was deemed necessary. Three research nurses to screen, consent, and follow patients and two tissue procurement technicians to procure the surgical specimens from the operating room and process the tissue selected by a pathologist per the TCGA protocol were hired. Prior to collecting tissue, inservice sessions were held for surgeons, operating room staff, histology staff, and pathologists. Results: Shortly after collection began, the NCI gave approval for the collection of other tumor types in anticipation of an expansion list of tumor types, which was released in October 2009. The Table below lists the different tumor types that have successfully been collected and passed the stringent quality control requirements. Conclusions: In order to collect high-quality biospecimens in a community hospital setting it is essential to have dedicated staff for both screening, consenting, and following patients and for tissue handling. It is also necessary to educate and then maintain buy-in from the individuals and departments whose cooperation is required throughout the process. Tumor type # Eligible Glioblastoma multiforme 7 Serous cystadenocarcinoma 15 Squamous cell carcinoma 7 Lung adenocarcinoma 18 Colorectal adenocarcinoma 30 Infiltrating ductal carcinoma 5 Endometrial carcinoma 1 Total 83 No significant financial relationships to disclose.
First-line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide
Authors: J. R. Strosberg, J. Choi, N. Gardner, L. Kvols
Journal: Journal of Clinical Oncology (2008)

4612 Background: Pancreatic endocrine carcinomas (PECAs) are uncommon with an estimated annual incidence of 1/100,000. Approximately half are metastatic at diagnosis. Trials of cytotoxic chemotherapy have established the activity of several drugs, including streptozocin, doxorubicin, fluorouracil and dacarbazine. The oral agent temozolomide, which shares its active metabolite with dacarbazine, has also been studied in neuroendocrine tumors. The combination of capecitabine and temozolomide has been found to be synergistic for apoptosis in neuroendocrine cell lines. Early human data indicates that this combination is both effective and well tolerated. Methods: Patients with progressive metastatic PECAs received treatment with a combination of capecitabine (750mg/m2 twice daily on days 1–14) and temozolomide (200mg/m2 daily on days 10–14), on a 28 day cycle. Radiographic response rates were assessed by CT scans and evaluated according to RECIST criteria. Results: Between 9/2005 and 9/2007, 17 patients received this combination as front-line chemotherapy for metastatic PECAs. The median age was 58 (28–77) years. There were three gastrinomas (17%), two insulinomas (12%), two glucagonomas (12%), and ten nonfunctioning tumors (59%). Eight tumors were well-differentiated, two were moderately differentiated, and seven were not graded. All patients had an ECOG performance status of 0–1. Twelve patients (71%) had a partial response and five patients (29%) had stable disease. With a median follow-up of 12 months, there were no cases of disease progression. Only 1 patient (6%) experienced a grade 3/4 toxicity (idiosyncratic immune thrombocytopenia secondary to capecitabine). Conclusions: The combination of capecitabine and temozolomide appears to be a highly active and exceptionally well-tolerated front-line treatment for metastatic pancreatic endocrine carcinoma. No significant financial relationships to disclose.
Abstract P091: Atrial Fibrillation Prevalence and Clinical Correlates Among Diverse Hispanic/Latinos: The Hispanic Community Health Study / Study of Latinos (HCHS-SOL)
Authors: Farah Dawood, Carlos Rodriguez, Sylvia W Smoller, Alvaro Alonso, Emelia J Benjamin, Susan Heckbert, Elsayed Soliman, Martha L Daviglus, Katrina Swett, Neil Schneiderman
Journal: Circulation (2015)

Introduction: Hispanics are the largest minority ethnic group in the US. There is limited data on the epidemiology of AF on Hispanic/Latino populations. Previous studies examined Hispanics/Latinos as an aggregate group or only Mexicans. Methods and Results: Total of 16,415 adult men and women HCHS-SOL participants were included in the analyses (60% women, 59% age > 45 years) representative of major US Hispanic background groups: Cuban (CU), Dominican (DR), Mexican (MX), Puerto Rican (PR), Central American (CA), and South American (SA). AF was defined by 12-lead ECG and/or self-report of a physician diagnosis. Ethnic-specific AF prevalence rates were determined. Weighted sequential logistic regression models were adjusted for demographic factors (age, sex, education) and clinical variables (diabetes, hypertension, body mass index, tobacco use, and eGFR). Overall AF prevalence was 0.97% (n=162) with highest prevalence among DRs and PRs (1.8% and 2.5% respectively) and the lowest among MXs (0.30%). Diabetes,...
Combined regimen of temozolomide and liposomal pegylated doxorubicin in glioblastoma—Toxicity and efficacy
Authors: U. Bogdahn, T. Jauch, C. Beier, D. Beier, S. Gänβbauer, M. Glas, H. Koch, C. Wismeth, A. Steinbrecher, P. Hau
Journal: Journal of Clinical Oncology (2006)

11501 Background: Temozolomide (Temodar, TMZ) recently showed promising efficacy in an EORTC trial on first-line therapy of glioblastoma (Stupp R, 2005). Pegylated liposomal doxorubicin (Caelyx, PEG-DOX) was evaluated in patients with recurrent high-grade glioma and showed an overall response rate of 40% (Hau P, 2002). Therefore, a combination of both agents seems promising. Methods: TMZ was given orally 75 mg/m 2 daily during standard radiotherapy (initiation) and 150–200 mg/m2 days 1–5 in 28 days starting 4 weeks after radiotherapy (maintainance). PEG-DOX was given as a short-time infusion in a dose-escalation regimen once prior to radiotherapy and on days 1 and 15 starting 4 weeks after radiotherapy. PEG-DOX was escalated for 5 mg/m 2 in groups of three patients starting with 5 mg/m 2 (group 1) and a highest dose of 20 mg/m 2 (group 4). Results: In the dose escalation part of this study, the regime detailed above was feasible, tolerable, and able to induce objective responses and stabilizations in patients with glioblastoma. In the first treatment group (5 mg/m 2 of PEG-Dox), one out of 7 evaluable patients had a dose limiting toxicity (DLT). In the second, third and fourth treatment groups, the regimen was tolerated without DLT. Concerning efficacy in the “treated-patients” analysis of 18 patients, 1 had a partial response in MRI, and 12 patients had tumor stabilization 4 weeks after conclusion of radiotherapy. Only 5 patients progressed early. Twelve patients responded with progression free survival times of 13 to 76 weeks. One patient is still progression free after 120 weeks of treatment. Conclusion: As no DLT was observed in dose group 4, MTD was not reached and we proceed to the efficacy phase of the trial with PEG-DOX in a dose of 20 mg/m 2 . Seventeen patients are included so far. Results will be compared to the published study EORTC 26981/22981 (Stupp R et al., 2005) which did set a new standard in the first-line treatment of glioblastoma as survival times of more than 14 months and a 2-year overall survival of 26% were reached. Regarding the promising preliminary survival data of study RNOP-09, we expect even better results with the regimen used in this protocol. [Table: see text]